DIRECT YOUR CARE, DEMAND SEQUENCING
Bryce Olson was diagnosed with aggressive stage 4 prostate cancer. When the standard of care didn’t work, Bryce turned to genomic sequencing which allowed his doctors to identify specific molecular drivers of his disease and identify specific treatments and clinical trials that were a better fit for his specific cancer.
“The driver of my cancer was hidden in my DNA. I asked my doctors to ‘Sequence Me.’ The insights from genomic sequencing opened new doors and saved my life. Fight cancer differently with data.”
Improve your Genomic IQ
Meet GIA (our Genomic Information Assistant from Clear Genetics). GIA is the first clinical-grade, HIPAA-compliant chatbot that is focused on educating cancer patients about the power of genomics, answering your questions, and helping you take the next steps towards improving your outcomes.
Click the blue GIA chat button in the bottom right corner of your screen.
Clear Genetics is a software company that is building technology, including an AI-driven platform, to scale the delivery of genetic and genomic services. They are driven to make genomics more accessible and offer thoughtful solutions to improve patient access to cutting-edge research.
JOIN THE MOVEMENT
Wear it to your next doctor‘s appointment and start the conversation about getting the DNA of your cancer profiled. Get on the path to precision medicine. Go beyond the standard. Be your own best advocate and demand to be sequenced.
INDIVIDUALIZE YOUR CARE – DEMAND SEQUENCING
Read these frequently asked questions, download the battle card and build confidence to understand the science, open new doors, and overcome objections or pushback. Be empowered and get more personalized care.
Absolutely! You are helping accelerate cancer research and drug development by doing this. Almost all of the companies that provide these tests partner with bio-pharma clients throughout each stage of drug research and development, from target discovery to commercial launch. We need to develop better drugs, faster. Broad testing of patients would make more data available to bio-pharma companies, accelerating the pace of research and the identification
Foundation Medicine has reported on that. Of the 79,000 cancer patients FMI tested in 2017, 38% percent were matched with an FDA approved therapy, 83% percent were matched with at least one relevant clinical trial, and all of them had at least one of those two outcomes.
Each individual cancer is unique and test results vary depending on the tumor type. When applicable, test results may help identify the following insights.
1. New insights into the preferred ‘on-label’ standard of care therapies. This means therapies approved to treat your specific tumor type and shown to be effective in targeting one or more of the alterations found by
2. New insights into off-label drugs: These are therapies approved in another tumor type (i.e. breast cancer) but possibly effective in targeting one or more of the genomic alterations found by the test that occur in your tumor (i.e. prostate cancer.)
3. A clinical trial evaluating therapies under development which may work by targeting an alteration found by the test that is in your tumor.
There’s new innovation going on in this space. Most of the commercial diagnostic test companies listed earlier will offer clinical trial matching as part of their report back to patients and doctors. Other good sources include ClinicalTrials.gov, which is a database of privately and publicly funded clinical studies conducted around the world (though a little challenging to use), Massive Bio that uses artificial intelligence to help match you to clinical trials that cater
No. Anybody with advanced cancer can demand and receive this. If your insurance doesn’t cover it, ask for financial assistance from the place doing the test.
This isn’t a trade-off between speed and safety. This is about getting medicines designed specifically for patients who express biological characteristics (biomarkers) that increase the odds that a treatment will actually work for them. FDA is streamlining approvals for these treatments and personalized medicine can arguably have better safety and efficacy profiles than one-size fits all medicine of today.
Disclaimer: SequenceMe.org provides this information as a service. This information and material is strictly for educational purposes only and is not intended as medical advice, is not intended to take the place of medical professionals, or the recommendations of your healthcare team for prevention, diagnosis and treatment of medical issues. We strongly suggest consulting your healthcare team if you have questions about your specific care.
KEEP UP WITH WHAT’S HAPPENING
As an advanced cancer patient who also works for one of the most innovative tech companies on the planet, Bryce lives on the edge of…Read More
Bryce Olson was recently featured on KATU Channel 2 News in Portland, Oregon. Watch Bryce’s story and learn how gene testing helped Bryce. “The message I just really want to deliver is: demand sequencing. Demand genomic sequencing.”Read More